Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice

Derek Weycker1 Xiaoyan Li2 Gail DeVecchis Wygant2 Theodore Lee3 Melissa Hamilton2 Xuemei Luo4 Lien Vo2 Jack Mardekian3 Xianying Pan5 Leah Burns2 Mark Atwood1 Ahuva Hanau1 Alexander T. Cohen6

1Policy Analysis Inc. (PAI), Brookline, Massachusetts, United States
2Bristol-Myers Squibb, Lawrenceville, New Jersey, United States
3Pfizer Inc., New York, New York, United States
4Pfizer Inc., Groton, Connecticut, United States
5Bristol-Myers Squibb, Wallingford, Connecticut, United States
6Guy’s and St. Thomas’ Hospitals, London, United Kingdom

Address for correspondence Derek Weycker, PhD, Policy Analysis Inc. (PAI), Four Davis Court, Brookline, Massachusetts, 02445, United States (e-mail: dweycker@pai2.com).


ERRATUM

The authors have brought to the publisher’s attention that there were some errors in ► Fig. 1 of the article and ► Table 1 of the Supplementary Material published in the above article in Thrombosis and Haemostasis, Volume 118, Number 8, 2018 (DOI: 10.1055/s-0038-1673689). The corrected figure and table appear as follows:

ISSN 0340-6245.
Fig. 1  Selection of patients receiving apixaban or warfarin as outpatient therapy for VTE. IVCF, inferior vena cava filter; OAC, oral anticoagulant; PAC, parenteral anticoagulant; VTE, venous thromboembolism.